Arthneeti
AH

Amrutanjan Health Care Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Amrutanjan Health Care Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.

Price₹510
Market cap₹1.4K Cr
P/E23.0
Updated24 Sept 2026
Read4 min read

Based on Amrutanjan Health Care Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Net Sales Q1 FY27: Rs. EBITDA and Operating Margin: The presentation does not explicitly provide EBITDA or operating margin figures for Q1 FY27.

From Amrutanjan Health Care Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

- Net Sales Q1 FY27: Rs. 102.97 Cr, up 9.48% YoY (Rs. 94.05 Cr in Q1 FY26) [Page 15] - OTC Products Net Sales Q1 FY27: Rs. 57.26 Cr, slight growth from Rs. 56.97 Cr YoY [Page 16] - Comfy (Women’s Hygiene & Personal Care) Net Sales Q1 FY27: Rs. 33.80 Cr, up 18.14% YoY (Rs. 28.61 Cr in Q1 FY26) [Page 16] - Beverages Net Sales Q1 FY27: Rs. 8.64 Cr, up 11.34% YoY (Rs. 7.76 Cr in Q1 FY26) [Page 17] - Hydration Drinks Net Sales Q1 FY27: Rs. 8.04 Cr, up 13.88% YoY (Rs. 7.06 Cr in Q1 FY26) [Page 17] - Pain Management category volume growth Q1 FY27: -3.4% vs. +6.6% in Q1 FY26 [Page 20] - New launches (Razors & Plastry) revenue Q1 FY27: Rs. 3 Cr for razors, Rs. 1.12 Cr for Plastry; annual projection Rs. 15 Cr and Rs. 10 Cr respectively [Pages 20, 9] **Outlook:** - Confident of double-digit revenue and operating profit growth for FY27 [Page 21]

2 more points management made on revenue & sales performance

Profitability & Margins

See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Commissioned a new Greenfield Sanitary Napkin Manufacturing Facility in Telangana.
  • Investment amount: ₹150 crore.
  • Facility size: Spread over 10 acres with 1.4 lakh sq. ft. built-up area.
  • Plant features two fully automated high-speed production lines from Japan.
  • This is Amrutanjan’s fifth manufacturing plant.
  • The facility is recently commissioned (as of the quarter ended 30th June 2026).
  • The plant aims to strengthen feminine hygiene product manufacturing under the Comfy brand.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation for the quarter ended 30th June 2026 does not explicitly report on order book, order inflow, or pending orders. The presentation focuses primarily on: - Quarterly financial performance, including net sales and profit metrics. - Segment-wise sales growth and product performance. - New product launches and their market acceptance.

2 more points management made on order book & pipeline

Amrutanjan Health Care Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹150 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Amrutanjan Health Care Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules Ltd (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

  • Aptus Pharma Ltd (Q1 FY27)

    Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…

  • RPG Life Sciences Ltd (Q1 FY27)

    Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…

  • SMS Pharmaceuticals Ltd (Q1 FY27)

    Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Amrutanjan Health Care Ltd Q1 FY27 results?

Net Sales Q1 FY27: Rs. EBITDA and Operating Margin: The presentation does not explicitly provide EBITDA or operating margin figures for Q1 FY27.

What is Amrutanjan Health Care Ltd share price analysis?

Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.

Is Amrutanjan Health Care Ltd planning capital expenditure?

Commissioned a new Greenfield Sanitary Napkin Manufacturing Facility in Telangana. - Investment amount: ₹150 crore. - Facility size: Spread over 10 acres with 1.4 lakh sq.

Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.